Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Omaha, Nebraska 68131


The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.


Inclusion Criteria: - Women at least 19 years old - Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease. - Able and willing to provide informed consent Exclusion Criteria: - Pregnancy or breastfeeding - Known CHD - Currently taking clopidogrel or ticlopidine - Use of heparin, warfarin, or glycoprotein IIb/IIa inhibitors within previous 96 hours - Allergy or hypersensitivity to salicylates - Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks - Currently participating in another investigational drug or device study



Primary Contact:


Backup Contact:


Location Contact:

Omaha, Nebraska 68131
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.